Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors

Trial Profile

Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Ribociclib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 28 Aug 2017 Planned initiation date changed from 10 Aug 2017 to 10 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top